Latest News and Press Releases

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

Opus Genetics to Participate in Leading Medical Conferences in May 2026

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Long-Term Financing by Oberland Capital

Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

Opus Genetics to Present at Upcoming Investor Conferences in March 2026

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting